By Colin Kellaher

 

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Wednesday said it is ending the development of pimodivir, an investigational antiviral treatment for influenza A infection, after disappointing study results.

Janssen said interim analyses of a Phase 3 study in hospitalized patients with influenza A found that pimodivir in combination with the standard of care was very unlikely to show an added benefit compared to standard-of-care treatment alone.

The company said it is halting the trial in hospitalized patients, along with a parallel study in outpatients with influenza A.

Janssen licensed pimodivir in 2014 from Boston drug maker Vertex Pharmaceuticals Inc. in a deal that included an upfront payment of $30 million, along with contingent development and commercial milestone payments.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

September 02, 2020 09:38 ET (13:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Vertex Pharmaceuticals Charts.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Vertex Pharmaceuticals Charts.